Generic Drug Labeling Claims Not Preempted By Mensing

Law360, New York (June 14, 2013, 8:27 PM EDT) -- A California appeals court Thursday allowed a woman's suit to move forward alleging that Teva Pharmaceuticals USA Inc. and others failed to warn of potential safety issues with a generic osteoporosis drug, finding her claims were not preempted by the U.S. Supreme Court's Mensing decision.

The California Court of Appeal for the Fourth Appellate District ruled that federal law did not preempt claims made by Olga Pickerie against several makers of a generic form of the osteoporosis drug Fosamax. Pickerie alleges that taking the drug caused...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.